ClinicalTrials.gg
CompletedNCT04255433SURPASS-CVOTUpdated Jul 8, 2026Results posted

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

A Phase 3 interventional study of Tirzepatide and Dulaglutide in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 635 sites in 31 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13,299
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
Largest of 43
13,299 · median 160
Started
2020
with 4 others
Phase 3
17 of 43
1 open now
Registered
16th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 5 that started in 2020, is one of 17 in phase 3, and was the 16th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
  • Glucose Metabolism Disorders
  • Metabolic Diseases
  • Endocrine System Diseases
  • Hypoglycemic Agents
  • Physiological Effects of Drugs
  • Tirzepatide
  • Incretins
  • Glucagon-Like Peptide 1
  • Gastric Inhibitory Polypeptide
  • Hormones
  • Hormones, Hormone Substitutes, and Hormone Antagonists
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women at least 40 years old with a diagnosis of type 2 diabetes
  • Established cardiovascular disease, including at least 1 of the following:

    • Coronary artery disease (CAD) with any of the following:

      • Documented history of spontaneous myocardial infarction (MI)
      • ≥50% stenosis in 1 or more major coronary arteries, determined by invasive angiography
      • ≥50% stenosis in 2 or more major coronary arteries, determined by computed tomography coronary angiography (CTCA)
      • History of surgical or percutaneous coronary revascularization procedure
    • Cerebrovascular disease - any of the following:

      • Documented history of ischemic stroke
      • Carotid arterial disease with ≥50% stenosis, documented by carotid ultrasound, magnetic resonance imaging (MRI), or angiography
      • Carotid stenting or surgical revascularization
    • Peripheral arterial disease with either of the following:

      • Intermittent claudication and ankle-brachial index \<0.9
      • Prior nontraumatic amputation or peripheral vascular procedure (eg, stenting or surgical revascularization), due to peripheral arterial ischemia
    • Note: Supporting medical documentation is required in all instances
  • ≥7% (≥53 mmol/mol) and ≤10.5% (≤91.3 mmol/mol) based on central laboratory assessment at screening
  • (BMI) ≥25 kg/m2
  • At the time of signing the : use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.

    • Male patients: Men, regardless of their fertility status, with nonpregnant women of (WOCBP) partners must agree to either remain abstinent (if this is their preferred and usual lifestyle) or use condoms, as well as 1 additional highly effective (less than 1% failure rate) method of contraception (such as combination oral contraceptives, implanted contraceptives, or intrauterine devices) or effective method of contraception (such as diaphragms with spermicide or cervical sponges) for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 90 days following the last dose of study drug.

      • Men and their partners may choose to use a double-barrier method of contraception. (Barrier protection methods without concomitant use of a spermicide are not an effective or acceptable method of contraception. Thus, each barrier method must include use of a spermicide. It should be noted, however, that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these barrier methods are combined).
      • Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception.
    • Men with pregnant partners should use condoms during intercourse for the duration of the study and until the end of the estimated relevant potential exposure in WOCBP (90 days). Men should refrain from sperm donation for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 90 days following the last dose of study drug. Men who are in exclusively same-sex relationships (as their preferred and usual lifestyle) are not required to use contraception.
    • Female patients: Women of childbearing potential who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same-sex relationship without sexual relationships with males. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception. Otherwise, WOCBP participating must agree to use 2 forms of effective contraception, where at least 1 form is highly effective (less than 1% failure rate), for the entirety of the study. Contraception must continue following completion of study drug administration for the entirety of the study and for 30 days thereafter.

      • WOCBP participating must test negative for pregnancy prior to initiation of treatment as indicated by a negative serum pregnancy test at the screening visit followed by a negative urine pregnancy test within 24 hours prior to exposure.
      • Two forms of effective contraception, where at least 1 form is highly effective, (such as combination oral contraceptives, implanted contraceptives, or intrauterine devices) will be used. Effective contraception (such as male or female condoms with spermicide, diaphragms with spermicide, or cervical sponges) may be used as the second therapy. Barrier protection methods without concomitant use of a spermicide are not a reliable or acceptable method. Thus, each barrier method must include use of a spermicide (ie, condom with spermicide, diaphragm with spermicide, or female condom with spermicide). It should be noted that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these methods are combined.
    • Women not of childbearing potential may participate and include those who are:

      • infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis, or
      • - defined as either: A woman at least 40 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, AND a follicle-stimulating hormone >40 mIU/mL; or ii. A woman 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea; or A woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy.
  • In the investigator's opinion, are well motivated, capable, and willing to:

    • learn how to self-inject treatment (tirzepatide or dulaglutide), as required for this protocol (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the study drug; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the study drug),
    • inject study drug weekly,
    • have a sufficient understanding of 1 of the provided languages of the country such that they will be able to complete the patient questionnaires, and
    • make themselves available for the duration of the study, and who will comply with the required study visits.
  • Capable of giving signed informed consent

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus
  • Have uncontrolled diabetes requiring immediate therapy (such as diabetic ketoacidosis) at screening or randomization, in the judgment of the physician
  • Have had 1 or more events of severe hypoglycemia and/or 1 or more events of hypoglycemia unawareness within 6 months prior to screening
  • Are currently planning treatment for diabetic retinopathy and/or macular edema.
  • Have been hospitalized for congestive heart failure (CHF) within 2 months prior to screening
  • Have chronic Functional Classification IV CHF
  • Are currently planning a coronary, carotid, or peripheral artery revascularization
  • Had chronic or acute pancreatitis any time prior to screening, irrespective of etiology
  • Have a known gastric emptying abnormality such as severe gastroparesis or gastric outlet obstruction, or have undergone or currently planning any gastric bypass (bariatric) surgery or restrictive bariatric surgery
  • Have acute or chronic hepatitis, signs or symptoms of any other liver disease, an (ALT) level ≥3 times the (ULN) for the reference range, as determined by the central laboratory (Note: Patients with nonalcoholic fatty liver disease are eligible to participate if their ALT level is \<3 times the ULN for the reference range)
  • Have known chronic severe renal failure (defined as a known estimated (eGFR) \<15 mL/minute/1.73 m2) or are on chronic dialysis
  • Have evidence of a significant, uncontrolled endocrine abnormality (eg, thyrotoxicosis or adrenal crises)
  • Have a family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (MTC) or personal history of nonfamilial MTC
  • Have a serum calcitonin level at screening of: (based on central laboratory results)

    • ≥20 ng/L at Visit 1, if eGFR ≥60 mL/min/1.73 m2, or
    • ≥35 ng/L at Visit 1, if eGFR \<60 mL/min/1.73 m2
  • Have a history of an active or untreated or are in remission from a clinically significant malignancy for less than 5 years. An exception for this criterion is basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer
  • Have a history of any other condition (such as known drug or alcohol abuse or psychiatric disorder) that, in the opinion of the investigator, may preclude the patient from following and completing the protocol
  • Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or awaiting an organ transplant
  • Have any other condition (eg, ) that is a to any incretin or glucagon-like peptide-1 (GLP-1) receptor agonist (RA)
  • Have had an MI, percutaneous coronary revascularization procedure, ischemic stroke, carotid stenting or surgical revascularization, nontraumatic amputation, or peripheral vascular procedure (eg, stenting or surgical revascularization) less than 60 days prior to screening
  • Have had coronary artery bypass graft surgery less than 5 years prior to screening
  • Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hematological conditions that may interfere with measurement
  • Treatment with GLP-1 RA or pramlintide, in a period of 3 months prior to Visit 1
  • Discontinuation of GLP-1 RA or pramlintide, due to intolerability any time prior to Visit 1
  • Are currently enrolled in any other clinical study involving an product or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have participated within the last 30 days in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed
  • Have previously completed or withdrawn from this study or randomized into any other study investigating tirzepatide
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
13,299 participants (actual)

Study arms

  • Experimental
    Tirzepatide - Maximum Tolerated Dose (MTD)

    Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered as subcutaneous (SC) injection once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or MTD tolerated by the participant (5 mg QW or 10 mg QW) for up to 5 years.

    Drug: Tirzepatide

  • Experimental
    1.5 mg Dulaglutide

    Participants received 1.5 mg dulaglutide administered as SC injection QW for up to 5 years.

    Drug: Dulaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]

    Number of participants with first occurrence of Clinical Endpoint Committee (CEC), a composite endpoint i.e., from time of randomization to first occurrence of cardiovascular (CV) death, myocardial infarction and stroke combined data was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Time frame: From randomization (week 0) up to week 259

Secondary outcomes

  1. Number of Participants From Randomization to Time to Occurrence of All-Cause Death

    The number of participants from randomization to time to occurrence of Clinical Endpoint Committee (CEC) confirmed all-cause death was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of all-cause death during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Time frame: From randomization (week 0) up to week 259

  2. Number of Participants From Randomization to Time of Occurrence of CV Death

    Number of participants from time of randomization to time to occurrence of CEC confirmed CV death was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of CV death during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Time frame: From randomization (week 0) up to week 259

  3. Number of Participants From Randomization to Time to First Occurrence of Myocardial Infarction (MI)

    The number of participants from randomization to first occurrence of CEC confirmed MI was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of nonfatal MI during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Time frame: From randomization (week 0) up to week 259

  4. Number of Participants From Randomization toTime to First Occurrence of Stroke

    The number of participants from randomization to first occurrence of CEC confirmed stroke was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of nonfatal stroke during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Time frame: From randomization (week 0) up to week 259

  5. Number of Participants From Randomization to Time to First Occurrence of the Expanded Composite of CV Death, MI, Stroke or Coronary Revascularization (MACE-4)

    The number of participants from randomization to first occurrence of MACE-4 was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Time frame: From randomization (week 0) up to week 259

  6. Number of Participants From Randomization to Time to First Occurrence of CV Deaths or Heart Failure Events Requiring Hospitalization and/or Urgent Heart Failure Visits

    The number of participants from randomization to first occurrence of Clinical Endpoint Committee (CEC) confirmed heart failure requiring hospitalisation or urgent heart failure was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Time frame: From randomization (week 0) up to week 259

  7. Number of Participants From Randomization to Time to First Occurrence of Revascularization

    The number of participants from randomization to first occurrence of coronary revascularization was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of revascularization during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Time frame: From randomization (week 0) up to week 259

  8. Number of Participants From Randomization to Time to First Occurrence of New or Worsening Nephropathy

    New or worsening nephropathy (Composite Endpoint 1) was defined as the first occurrence of any of the following events: persistent macroalbuminuria (urine albumin-to-creatinine ratio \>300 mg/g), persistent doubling of serum creatinine with eGFR \<45 mL/min/1.73 m², onset of end-stage renal disease (including initiation of chronic dialysis or kidney transplantation), or death due to renal disease. Time to event was defined as the number of days from the date of randomization to the first occurrence any of these events. during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Time frame: From randomization (week 0) up to week 259

  9. Change From Baseline to 36 Months in Estimated Glomerular Filtration Rate (eGFR) in Patients With High or Very-high Risk Chronic Kidney Disease (CKD)

    Change from baseline in eGFR calculated as difference between value at 36 months and baseline value. Participants included in this analysis were classified as having high or very high risk of chronic kidney disease at baseline based on their kidney function (eGFR) and urine albumin-to-creatinine ratio (UACR). High risk included participants with eGFR 45 to less than 60 milliliters/minutes/1.73 square metres (mL/min/1.73 m²) and UACR greater than 30 mg/g, or eGFR 60 mL/min/1.73 m² or higher with UACR greater than 300 mg/g. Very high risk included participants with eGFR less than 45 mL/min/1.73 m² or severely increased UACR (greater than 300 mg/g). These criteria are associated with an increased risk of worsening kidney function. Least squares (LS) mean was calculated using analysis of covariance (ANCOVA) model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline sodium-glucose cotransporter-2 (SGLT-2) Use Flag.

    Time frame: Baseline, 36 Months

  10. Change From Baseline to 36 Months in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Change in HbA1c from baseline up to 36 months during in-trial period were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death. LS mean was calculated using ANCOVA model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares).

    Time frame: Baseline, 36 Months

  11. Percent Change From Baseline to 36 Months in Body Weight

    LS mean was calculated using ANCOVA model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares)

    Time frame: Baseline, 36 Months

  12. Percent Change From Baseline to 36 Months in Urinary Albumin to Creatinine Ratio (UACR)

    Urine samples were collected for the analysis of UACR. UACR (gram per kilograms \[g/kg\]) was calculated as urine albumin (gram per liter \[g/L\])/urine creatinine (kg/L). Percent change from baseline at 36 months was calculated as: \[(UACR at 36 months - baseline UACR) / baseline UACR\] × 100. LS mean was calculated using ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares).

    Time frame: Baseline, 36 Months

  13. Percent Change From Baseline to 24 Months in Blood Lipids (Total Cholesterol (TC), Low-Density Lipoprotein Cholesterol (LDL-C), High-Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG))

    Blood samples of participants who had fasted for 12 to 14 hours were collected for lipid profile (TC, LDL-C, HDL-C, TG) assessment. The lipid profile asesses the risk of heart disease. Percent change from baseline = 100\*(post-baseline assessment - baseline assessment)/baseline assessment. LS mean was calculated using ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment + Analysis Country + Baseline SGLT-2i Use Flag.

    Time frame: Baseline, 24 Months

07

Results

Posted Jul 8, 2026

Participant flow

Participant flow — Overall Study
MilestoneTirzepatide - Maximum Tolerated Dose (MTD)1.5 mg Dulaglutide
Started66486651
Safety population66476647
Modified intention-to-treat (mitt) population65866579
Completed65246505
Not completed124146
Withdrew: Withdrawal by subject1715
Withdrew: Lost to follow-up4559
Withdrew: Discontinued due to ''randomization in error''6272

Outcome measures

PrimaryNumber of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]

Number of participants with first occurrence of Clinical Endpoint Committee (CEC), a composite endpoint i.e., from time of randomization to first occurrence of cardiovascular (CV) death, myocardial infarction and stroke combined data was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

Time frame:
From randomization (week 0) up to week 259
Reported as:
Number · participants
Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]
participantsTirzepatide (MTD)1.5 mg Dulaglutide
Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]801862
SecondaryNumber of Participants From Randomization to Time to Occurrence of All-Cause Death

The number of participants from randomization to time to occurrence of Clinical Endpoint Committee (CEC) confirmed all-cause death was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of all-cause death during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

Time frame:
From randomization (week 0) up to week 259
Reported as:
Number · participants
Number of Participants From Randomization to Time to Occurrence of All-Cause Death
participantsTirzepatide (MTD)1.5 mg Dulaglutide
Number of Participants From Randomization to Time to Occurrence of All-Cause Death566669
SecondaryNumber of Participants From Randomization to Time of Occurrence of CV Death

Number of participants from time of randomization to time to occurrence of CEC confirmed CV death was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of CV death during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

Time frame:
From randomization (week 0) up to week 259
Reported as:
Number · participants
Number of Participants From Randomization to Time of Occurrence of CV Death
participantsTirzepatide (MTD)1.5 mg Dulaglutide
Number of Participants From Randomization to Time of Occurrence of CV Death367408
SecondaryNumber of Participants From Randomization to Time to First Occurrence of Myocardial Infarction (MI)

The number of participants from randomization to first occurrence of CEC confirmed MI was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of nonfatal MI during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

Time frame:
From randomization (week 0) up to week 259
Reported as:
Number · participants
Number of Participants From Randomization to Time to First Occurrence of Myocardial Infarction (MI)
participantsTirzepatide (MTD)1.5 mg Dulaglutide
Number of Participants From Randomization to Time to First Occurrence of Myocardial Infarction (MI)311357
SecondaryNumber of Participants From Randomization toTime to First Occurrence of Stroke

The number of participants from randomization to first occurrence of CEC confirmed stroke was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of nonfatal stroke during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

Time frame:
From randomization (week 0) up to week 259
Reported as:
Number · participants
Number of Participants From Randomization toTime to First Occurrence of Stroke
participantsTirzepatide (MTD)1.5 mg Dulaglutide
Number of Participants From Randomization toTime to First Occurrence of Stroke229249
SecondaryNumber of Participants From Randomization to Time to First Occurrence of the Expanded Composite of CV Death, MI, Stroke or Coronary Revascularization (MACE-4)

The number of participants from randomization to first occurrence of MACE-4 was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

Time frame:
From randomization (week 0) up to week 259
Reported as:
Number · participants
Number of Participants From Randomization to Time to First Occurrence of the Expanded Composite of CV Death, MI, Stroke or Coronary Revascularization (MACE-4)
participantsTirzepatide (MTD)1.5 mg Dulaglutide
Number of Participants From Randomization to Time to First Occurrence of the Expanded Composite of CV Death, MI, Stroke or Coronary Revascularization (MACE-4)10891217
SecondaryNumber of Participants From Randomization to Time to First Occurrence of CV Deaths or Heart Failure Events Requiring Hospitalization and/or Urgent Heart Failure Visits

The number of participants from randomization to first occurrence of Clinical Endpoint Committee (CEC) confirmed heart failure requiring hospitalisation or urgent heart failure was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

Time frame:
From randomization (week 0) up to week 259
Reported as:
Number · participants
Number of Participants From Randomization to Time to First Occurrence of CV Deaths or Heart Failure Events Requiring Hospitalization and/or Urgent Heart Failure Visits
participantsTirzepatide (MTD)1.5 mg Dulaglutide
Number of Participants From Randomization to Time to First Occurrence of CV Deaths or Heart Failure Events Requiring Hospitalization and/or Urgent Heart Failure Visits512557
SecondaryNumber of Participants From Randomization to Time to First Occurrence of Revascularization

The number of participants from randomization to first occurrence of coronary revascularization was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of revascularization during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

Time frame:
From randomization (week 0) up to week 259
Reported as:
Number · participants
Number of Participants From Randomization to Time to First Occurrence of Revascularization
participantsTirzepatide (MTD)1.5 mg Dulaglutide
Number of Participants From Randomization to Time to First Occurrence of Revascularization527617
SecondaryNumber of Participants From Randomization to Time to First Occurrence of New or Worsening Nephropathy

New or worsening nephropathy (Composite Endpoint 1) was defined as the first occurrence of any of the following events: persistent macroalbuminuria (urine albumin-to-creatinine ratio \>300 mg/g), persistent doubling of serum creatinine with eGFR \<45 mL/min/1.73 m², onset of end-stage renal disease (including initiation of chronic dialysis or kidney transplantation), or death due to renal disease. Time to event was defined as the number of days from the date of randomization to the first occurrence any of these events. during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

Time frame:
From randomization (week 0) up to week 259
Reported as:
Number · participants
Number of Participants From Randomization to Time to First Occurrence of New or Worsening Nephropathy
participantsTirzepatide (MTD)1.5 mg Dulaglutide
Number of Participants From Randomization to Time to First Occurrence of New or Worsening Nephropathy373442
SecondaryChange From Baseline to 36 Months in Estimated Glomerular Filtration Rate (eGFR) in Patients With High or Very-high Risk Chronic Kidney Disease (CKD)

Change from baseline in eGFR calculated as difference between value at 36 months and baseline value. Participants included in this analysis were classified as having high or very high risk of chronic kidney disease at baseline based on their kidney function (eGFR) and urine albumin-to-creatinine ratio (UACR). High risk included participants with eGFR 45 to less than 60 milliliters/minutes/1.73 square metres (mL/min/1.73 m²) and UACR greater than 30 mg/g, or eGFR 60 mL/min/1.73 m² or higher with UACR greater than 300 mg/g. Very high risk included participants with eGFR less than 45 mL/min/1.73 m² or severely increased UACR (greater than 300 mg/g). These criteria are associated with an increased risk of worsening kidney function. Least squares (LS) mean was calculated using analysis of covariance (ANCOVA) model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline sodium-glucose cotransporter-2 (SGLT-2) Use Flag.

Time frame:
Baseline, 36 Months
Reported as:
Least squares mean · milliliters/minutes/1.73 square metres
Change From Baseline to 36 Months in Estimated Glomerular Filtration Rate (eGFR) in Patients With High or Very-high Risk Chronic Kidney Disease (CKD)
milliliters/minutes/1.73 square metresTirzepatide (MTD)1.5 mg Dulaglutide
Change From Baseline to 36 Months in Estimated Glomerular Filtration Rate (eGFR) in Patients With High or Very-high Risk Chronic Kidney Disease (CKD)-5.72 ± 0.437-8.90 ± 0.393
SecondaryChange From Baseline to 36 Months in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Change in HbA1c from baseline up to 36 months during in-trial period were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death. LS mean was calculated using ANCOVA model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares).

Time frame:
Baseline, 36 Months
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline to 36 Months in Hemoglobin A1c (HbA1c)
Percentage of HbA1cTirzepatide (MTD)1.5 mg Dulaglutide
Change From Baseline to 36 Months in Hemoglobin A1c (HbA1c)-1.66 ± 0.0211-0.88 ± 0.0235
SecondaryPercent Change From Baseline to 36 Months in Body Weight

LS mean was calculated using ANCOVA model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares)

Time frame:
Baseline, 36 Months
Reported as:
Least squares mean · percent change
Percent Change From Baseline to 36 Months in Body Weight
percent changeTirzepatide (MTD)1.5 mg Dulaglutide
Percent Change From Baseline to 36 Months in Body Weight-11.6 ± 0.122-4.82 ± 0.0995
SecondaryPercent Change From Baseline to 36 Months in Urinary Albumin to Creatinine Ratio (UACR)

Urine samples were collected for the analysis of UACR. UACR (gram per kilograms \[g/kg\]) was calculated as urine albumin (gram per liter \[g/L\])/urine creatinine (kg/L). Percent change from baseline at 36 months was calculated as: \[(UACR at 36 months - baseline UACR) / baseline UACR\] × 100. LS mean was calculated using ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares).

Time frame:
Baseline, 36 Months
Reported as:
Least squares mean · percent change
Percent Change From Baseline to 36 Months in Urinary Albumin to Creatinine Ratio (UACR)
percent changeTirzepatide (MTD)1.5 mg Dulaglutide
Percent Change From Baseline to 36 Months in Urinary Albumin to Creatinine Ratio (UACR)-26.42 ± 1.202-7.23 ± 1.641
SecondaryPercent Change From Baseline to 24 Months in Blood Lipids (Total Cholesterol (TC), Low-Density Lipoprotein Cholesterol (LDL-C), High-Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG))

Blood samples of participants who had fasted for 12 to 14 hours were collected for lipid profile (TC, LDL-C, HDL-C, TG) assessment. The lipid profile asesses the risk of heart disease. Percent change from baseline = 100\*(post-baseline assessment - baseline assessment)/baseline assessment. LS mean was calculated using ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment + Analysis Country + Baseline SGLT-2i Use Flag.

Time frame:
Baseline, 24 Months
Reported as:
Least squares mean · percent change
Percent Change From Baseline to 24 Months in Blood Lipids (Total Cholesterol (TC), Low-Density Lipoprotein Cholesterol (LDL-C), High-Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG))
percent changeTirzepatide (MTD)1.5 mg Dulaglutide
Total Cholesterol (TC)-4.09 ± 0.318-2.78 ± 0.324
Low-Density Lipoprotein Cholesterol (LDL-C)-1.61 ± 0.562-2.87 ± 0.550
High-Density Lipoprotein Cholesterol (HDL-C)9.34 ± 0.2842.45 ± 0.266
Triglycerides (TG)-24.18 ± 0.453-10.17 ± 0.537

Adverse events

Collected over Baseline Up to 259 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tirzepatide (MTD)568/6,648 (8.5%)2,117/6,647 (31.8%)4,718/6,647 (71%)
1.5 mg Dulaglutide670/6,651 (10.1%)2,121/6,647 (31.9%)4,297/6,647 (64.6%)
Most frequent serious events
Showing 10 of 1,537
Most frequent serious events
EventTirzepatide (MTD)1.5 mg Dulaglutide
PneumoniaInfections and infestations126/6647158/6647
Acute kidney injuryRenal and urinary disorders93/664792/6647
Covid-19Infections and infestations60/664785/6647
Covid-19 pneumoniaInfections and infestations62/664767/6647
Peripheral arterial occlusive diseaseVascular disorders59/664765/6647
Angina unstableCardiac disorders63/664758/6647
Cardiac failure chronicCardiac disorders62/664762/6647
Atrial fibrillationCardiac disorders57/664755/6647
Urinary tract infectionInfections and infestations57/664752/6647
Cholecystitis acuteHepatobiliary disorders56/664742/6647
Most frequent other events
Showing 10 of 19
Most frequent other events
EventTirzepatide (MTD)1.5 mg Dulaglutide
NauseaGastrointestinal disorders1665/66471484/6647
DiarrhoeaGastrointestinal disorders1644/66471258/6647
Decreased appetiteMetabolism and nutrition disorders1136/6647647/6647
Covid-19Infections and infestations1041/66471005/6647
ConstipationGastrointestinal disorders836/6647771/6647
VomitingGastrointestinal disorders757/6647637/6647
DyspepsiaGastrointestinal disorders658/6647540/6647
Weight decreasedInvestigations467/6647117/6647
Urinary tract infectionInfections and infestations442/6647462/6647
DizzinessNervous system disorders462/6647407/6647

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Tirzepatide (MTD)1.5 mg DulaglutideTotal
Mean64.00 ± 8.8364.10 ± 8.7264.10 ± 8.77
Sex: Female, Male
Sex: Female, Male(Participants)Tirzepatide (MTD)1.5 mg DulaglutideTotal
Female190319463849
Male474547059450
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tirzepatide (MTD)1.5 mg DulaglutideTotal
Hispanic or Latino200720034010
Not Hispanic or Latino432643168642
Unknown or Not Reported315332647
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tirzepatide (MTD)1.5 mg DulaglutideTotal
American Indian or Alaska Native489481970
Asian5805901170
Native Hawaiian or Other Pacific Islander9918
Black or African American111109220
White5349534810697
More than one race222648
Unknown or Not Reported8888176
Region of Enrollment
Region of Enrollment(Participants)Tirzepatide (MTD)1.5 mg DulaglutideTotal
Argentina8128151627
Australia194194388
Austria414081
Belgium6566131
Brazil310312622
Canada227227454
China175175350
Czechia114113227
France7674150
Germany489488977
Greece160160320
Hungary188187375
India117118235
Israel214214428
Italy108109217
Japan5050100
Mexico7927921584
Netherlands6365128
Poland224223447
Romania282283565
Russia177178355
Slovakia8182163
South Korea6565130
Spain204205409
Sweden494897
Taiwan8179160
Turkey (Türkiye)126124250
Ukraine375375750
United Kingdom393978
United States7507511501
08

Study locations

635 sites
  • University of Alabama at Birmingham Medical Center
    Birmingham, Alabama 35294-0012, United States
  • John Muir Medical Center - Concord Campus
    Concord, California 94520, United States
  • Valley Clinical Trials, Inc.
    Covina, California 91723, United States
  • AMCR Institute
    Escondido, California 92025, United States
  • Valley Research
    Fresno, California 93720, United States
  • NorCal Medical Research, Inc
    Greenbrae, California 94904, United States
  • UCSD - Altman Clinical and Translational Research Institute (ACTRI)
    La Jolla, California 92037, United States
  • First Valley Medical Group
    Lancaster, California 93534, United States
  • Monterey Endocrine & Diabetes Institute, Inc.
    Monterey, California 93940, United States
  • Riverside University Health System - Medical Center
    Moreno Valley, California 92555, United States
  • Diabetes Associates Medical Group
    Orange, California 92868, United States
  • Pasadena Clinical Research
    Pasadena, California 91105, United States
  • LCGK Research
    San Carlos, California 94070, United States
  • Norcal Endocrinology & Internal Medicine
    San Ramon, California 94583, United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • CMR of Greater New Haven, LLC
    Hamden, Connecticut 06517, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Orlando Heart & Vascular Institute, LLC
    Altamonte Springs, Florida 32714, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Encore Medical Research
    Hollywood, Florida 33024, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32204, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Accel Research Sites - St. Pete-Largo Clinical Research Unit
    Largo, Florida 33777, United States
  • Ocala Caridovascular Research
    Ocala, Florida 34474, United States
  • Cardiology Partners Clinical Research Institute - Palm Beach Gardens
    Palm Beach Gardens, Florida 33410, United States
  • Peace River Cardiovascular Center
    Port Charlotte, Florida 33952, United States
  • Professional Health Care of Pinellas
    St. Petersburg, Florida 33713, United States
  • Cardiology Partners Clinical Research Institute - Wellington
    Wellington, Florida 33449, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • Kaiser Permanente - Dutluth, GA
    Duluth, Georgia 30096, United States
  • NSC Research
    Johns Creek, Georgia 30024, United States
  • Physicians Research Associates
    Lawrenceville, Georgia 30045, United States
  • East Coast Institute for Research at The Jones Center
    Macon, Georgia 31210, United States
  • Atlanta Heart Specialists
    Tucker, Georgia 30084, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • VA Pacific Islands Health Care System
    Honolulu, Hawaii 96819, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Northwest Heart Clinical Research
    Arlington Heights, Illinois 60005, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Clinical Investigation Specialists
    Gurnee, Illinois 60031, United States
  • Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative
    Springfield, Illinois 62711, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50266, United States
  • The University of Kansas - Clinical Research Center
    Fairway, Kansas 66205, United States
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
  • Cotton O'Neil Mulvane
    Topeka, Kansas 66606, United States
  • Qualmedica Research
    Bowling Green, Kentucky 42101, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Qualmedica Research, LLC
    Owensboro, Kentucky 42301, United States
  • Ascension Saint Agnes Heart Care
    Baltimore, Maryland 21229, United States
  • MedStar Health Research Institute (MedStar Physician Based Research Network)
    Hyattsville, Maryland 20782, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Endocrine and Metabolic Consultants
    Rockville, Maryland 20852, United States
  • Brigham and Women's Hospital Diabetes Program
    Boston, Massachusetts 02115, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • ActivMed Practices and Research
    Methuen, Massachusetts 01844, United States
  • Infinity Medical Research
    North Dartmouth, Massachusetts 02747, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • St. John's Hospital
    Edina, Minnesota 55435, United States
  • M Health Fairview St. John's Hospital
    Maplewood, Minnesota 55109, United States
  • CentraCare Heart & Vascular Center
    Saint Cloud, Minnesota 56303, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC
    Springfield, Missouri 65807, United States
  • Mercy Research - Smith Glynn Callaway
    Springfield, Missouri 65807, United States
  • Billings Clinic
    Billings, Montana 59101, United States
  • Mercury Street Medical Group, PLLC
    Butte, Montana 59701, United States
  • VA Nebraska-Western Iowa Health Care System
    Omaha, Nebraska 68105, United States
  • University Of Nebraska Medical Center
    Omaha, Nebraska 68198-4130, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada 89128, United States
  • Palm Research Center Sunset
    Las Vegas, Nevada 89148, United States
  • Southern Nh Diabetes and Endocrinology
    Nashua, New Hampshire 03060, United States
  • Albany Medical College, Division of Community Endocrinology
    Albany, New York 12203, United States
  • Great Lakes Medical Research, LLC
    Westfield, New York 14787, United States
  • Atrium Health - Department of Family Medicine Research
    Charlotte, North Carolina 28207, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • PMG Research Inc., d/b/a PMG of Piedmont Healthcare
    Mooresville, North Carolina 28117, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 24801, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • Heritage Valley Medical Group, Inc.
    Beaver, Pennsylvania 15009, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Decpa, Llc
    Feasterville, Pennsylvania 19053, United States
  • Thomas Jefferson University - Clinical Research Institute
    Philadelphia, Pennsylvania 19107, United States
  • Northeast Endocrine Metabolic Associates
    Philadelphia, Pennsylvania 19114, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
    Pittsburgh, Pennsylvania 15236, United States
  • Cardiology Consultants of Philadelphia Yardley
    Yardley, Pennsylvania 19067, United States
  • Ralph H. Johnson VA Medical Center
    Charleston, South Carolina 29401, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • Accellacare - Mt Pleasant
    Mt. Pleasant, South Carolina 29464, United States
  • Monument Health Rapid City Hospital
    Rapid City, South Dakota 57701, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • PMG Research, Inc. d/b/a PMG Research of Knoxville
    Knoxville, Tennessee 37938, United States
  • Endocrine Clinic
    Memphis, Tennessee 38119, United States
  • Private Practice - Dr. Osvaldo A. Brusco
    Corpus Christi, Texas 78414, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States

Showing the first 100 of 635 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nissen SE, Wolski K, D'Alessio D, Weerakkody G, Kiljanski J, Wiese RJ, Pavo I, Cariou B, Nicholls SJ. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. JAMA Cardiol. 2026 Jun 1;11(6):544-552. doi: 10.1001/jamacardio.2026.0767. PubMed 41903177 ↗
  • Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Miller D, Nauck MA, Nishiyama H, Nissen SE, Sattar N, Weerakkody G, Wiese RJ, Zinman B, Zoungas S, Basile J, Davies MJ, Giorgino F, Kellerer M, Ji L, Varkonyi T, Menon V, Broder JC, Herschtal A, D'Alessio D; SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025 Dec 18;393(24):2409-2420. doi: 10.1056/NEJMoa2505928. PubMed 41406444 ↗
  • Khawaji A, A Jaly A, A Bakri H, Ravi R, Hattan A, Khawaji A, Najmi W. Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With >/= 20 Weeks Treatment Duration. J Obes. 2025 Jul 24;2025:3442754. doi: 10.1155/jobe/3442754. eCollection 2025. PubMed 40746703 ↗
  • Kaneko S. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. touchREV Endocrinol. 2022 Jun;18(1):10-19. doi: 10.17925/EE.2022.18.1.10. Epub 2022 Jun 16. PubMed 35949358 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jun 2025, 60 months.

Results were first posted in Jul 2026, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 60 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2020
First posted
Feb 5, 2020
StartActual
May 29, 2020
Primary completionActual
Jun 12, 2025
CompletionActual
Jun 12, 2025
Results first posted
Jul 8, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04255433
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
May 29, 2020
Primary completion
Jun 12, 2025
Completion
Jun 12, 2025
Results posted
Jul 8, 2026
Last update
Jul 8, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion